Compare CENX & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CENX | IRTC |
|---|---|---|
| Founded | 1995 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aluminum | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.8B |
| IPO Year | 2004 | 2016 |
| Metric | CENX | IRTC |
|---|---|---|
| Price | $56.90 | $116.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | $57.00 | ★ $207.54 |
| AVG Volume (30 Days) | ★ 2.2M | 625.6K |
| Earning Date | 05-22-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.71 |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $1,893,200,000.00 | $747,138,000.00 |
| Revenue This Year | $11.48 | $19.58 |
| Revenue Next Year | $12.88 | $15.95 |
| P/E Ratio | $139.71 | ★ N/A |
| Revenue Growth | N/A | ★ 26.24 |
| 52 Week Low | $13.05 | $92.52 |
| 52 Week High | $59.12 | $210.01 |
| Indicator | CENX | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 60.46 | 31.73 |
| Support Level | $27.33 | N/A |
| Resistance Level | N/A | $161.36 |
| Average True Range (ATR) | 3.35 | 5.55 |
| MACD | 0.08 | -0.63 |
| Stochastic Oscillator | 79.94 | 16.71 |
Century Aluminum Co produces primary aluminum standard grade and value-added products. The firm operates smelter facilities in the United States and Iceland. The majority of revenue is generated from Glencore, which agreed to purchase nearly all of Century Aluminum's North American production. Century purchases nearly all of its alumina from Glencore. The company produces high purity aluminum, standard-grade aluminum sow and tee bars, and value-added billet and foundry products. Century also owns a carbon anode production facility in the Netherlands.
iRhythm Holdings Inc formerly, iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.